keyword
MENU ▼
Read by QxMD icon Read
search

lmwh cancer

keyword
https://www.readbyqxmd.com/read/29661489/comparison-of-the-effects-of-edoxaban-an-oral-direct-factor-xa-inhibitor-on-venous-thromboembolism-between-patients-with-and-without-cancer
#1
Satoshi Ikeda, Seiji Koga, Yuki Yamagata, Masamichi Eguchi, Daisuke Sato, Takahiro Muroya, Tsuyoshi Yonekura, Akira Tsuneto, Tsuyoshi Yoshimuta, Yuji Koide, Hiroaki Kawano, Koji Maemura
BACKGROUND: Venous thromboembolism (VTE) is a frequent and serious complication of cancer. The current guidelines in the USA and Europe recommend low-molecular weight heparin (LMWH) for the treatment of cancer-associated VTE. In Japan, LMWH is not given for the treatment of VTE; instead edoxaban, an oral direct factor Xa inhibitor, was approved for the treatment of VTE in September 2014. However, the efficacy and safety of the factor Xa inhibitor in cancer patients have not been fully elucidated...
April 13, 2018: Journal of Cardiology
https://www.readbyqxmd.com/read/29627861/patients-experience-of-living-with-cancer-associated-thrombosis-in-spain-pelicanos
#2
Carme Font, Annmarie Nelson, Tanya Garcia-Fernandez, Hayley Prout, Peter Gee, Simon Noble
INTRODUCTION: The previously reported Patients' Experience of LIving with CANcer-associated thrombosis (PELICAN) identified several areas of unmet clinical and support need for cancer patients diagnosed with venous thromboembolism (VTE) in the UK. It is not known whether such experiences are restricted to one particular country's healthcare system and culture. We therefore undertook an evaluation of patients' experience of cancer-associated thrombosis (CAT) within a Spanish setting. METHODS: Twenty consecutive Spanish patients with CAT were interviewed about their experiences of living with CAT as per the previous PELICAN study...
April 7, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29617053/efficacy-and-safety-of-rivaroxaban-compared-to-enoxaparin-in-treatment-of-cancer-associated-venous-thromboembolism
#3
Benjamin Simmons, Waldemar Wysokinski, Rayya A Saadiq, Dalene Bott-Kitslaar, Stanislav Henkin, Ana Casanegra, Charles Lenz, Paul Daniels, Haraldur Bjarnason, Emily Vargas, David Hodge, Sara J Holton, James R Cerhan, Charles Loprinzi, Robert McBane
BACKGROUND: Low molecular weight heparin (LMWH) is the guideline endorsed treatment for cancer associated venous thromboembolism (cVTE). Study objectives were to compare the efficacy and safety of rivaroxaban and enoxaparin in cVTE. METHODS: Using a cohort study design, consecutive patients with cVTE (3/1/2013-7/31/2016), enrolled in the Mayo Thrombophilia Clinic Direct Oral Anticoagulants Registry were compared to contemporary cancer patients receiving enoxaparin...
April 4, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29544692/-cancer-and-venous-thromboembolism-recurrence-the-keys-for-an-optimal-management
#4
REVIEW
Isabelle Mahé, Ygal Benhamou, Hélène Helfer, Jean Chidiac
Low-molecular-weight heparins (LMWH) are to date the standard for 3-to-6-month treatment of cancer-associated thrombosis (CAT) as they are consistently recommended by international clinical practice guidelines. Despite the high risk of VTE recurrence and death in patients with cancer and the favorable benefit-risk profile of LMWH demonstrated in randomized-control studies, the implementation of treatment guidelines remains insufficient in the clinical practice. A systematic review of observational studies, registries and surveys reveals that approximately only 50% of patients with CAT are treated according to practice guidelines while both physicians and patients may be accountable for this situation...
March 12, 2018: Bulletin du Cancer
https://www.readbyqxmd.com/read/29542333/development-of-redox-responsive-theranostic-nanoparticles-for-near-infrared-fluorescence-imaging-guided-photodynamic-chemotherapy-of-tumor
#5
Xiaoye Yang, Xiaoqun Shi, Jianbo Ji, Guangxi Zhai
The development of imaging-guided smart drug delivery systems for combinational photodynamic/chemotherapy of the tumor has become highly demanded in oncology. Herein, redox-responsive theranostic polymeric nanoparticles (NPs) were fabricated innovatively using low molecular weight heparin (LWMH) as the backbone. Chlorin e6 (Ce6) and alpha-tocopherol succinate (TOS) were conjugated to LMWH via cystamine as the redox-sensitive linker, forming amphiphilic Ce6-LMWH-TOS (CHT) polymer, which could self-assemble into NPs in water and encapsulate paclitaxel (PTX) inside the inner core (PTX/CHT NPs)...
November 2018: Drug Delivery
https://www.readbyqxmd.com/read/29540105/clotassist-a-program-to-treat-cancer-associated-thrombosis-in-an-outpatient-pharmacy-setting
#6
Jacob C Easaw, Susan McCall, Adrian Azim
Stable cancer patients diagnosed with a pulmonary embolus or deep vein thrombosis are commonly referred to the emergency department for management. This practice strains an already overburdened emergency department and is associated with long wait times and poor disease/injection education for patients. This pilot study sought to determine if stable cancer patients with newly diagnosed cancer-associated thrombosis could be effectively managed by community-based pharmacists who followed an evidence-based protocol to prescribe and initiate low-molecular weight heparin therapy...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29521068/real-life-use-of-thromboprophylaxis-in-patients-hospitalized-for-pulmonary-disorders-a-single-center-retrospective-study
#7
Robert F Łukaszuk, Krzysztof Plens, Anetta Undas
BACKGROUND: Underuse of thromboprophylaxis in hospitalized medical patients is still common worldwide. Little is known about the use of thromboprophylaxis in patients with pulmonary diseases in everyday hospital practice. OBJECTIVES: The aim of this study was to assess the use of pharmacological prophylaxis of venous thromboembolism (VTE) in real-life patients with pulmonary diseases. MATERIAL AND METHODS: In this retrospective study, 2 validated scoring systems, i...
February 2018: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/29506866/direct-oral-anticoagulant-doac-versus-low-molecular-weight-heparin-lmwh-for-treatment-of-cancer-associated-thrombosis-cat-a-systematic-review-and-meta-analysis
#8
Ang Li, David A Garcia, Gary H Lyman, Marc Carrier
INTRODUCTION: It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer-associated venous thromboembolism (VTE). We aim to synthesize existing literature that compared DOACs versus LMWHs in this high-risk population. MATERIALS AND METHODS: We conducted a systematic review using EMBASE, MEDLINE and CENTRAL for all observational studies and randomized controlled trials (RCTs) (PROSPERO: CRD42017080898)...
March 2, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29485330/cancer-patients-experiences-of-living-with-venous-thromboembolism-a-systematic-review-and-qualitative-thematic-synthesis
#9
Naima B Benelhaj, Ann Hutchinson, Anthony M Maraveyas, Julie D Seymour, Muhammad Waqas Ilyas, Miriam J Johnson
BACKGROUND: Cancer-associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6 months. Most studies focus on prophylaxis and treatment; few have explored the patients' experience. AIMS: To identify and synthesise the available literature concerning patients' experience of cancer-associated thrombosis. DESIGN: Systematic literature review and qualitative thematic synthesis. DATA SOURCE: MEDLINE, Embase, CINAHL, PsycINFO (until 10/2016; limited to English) were searched...
February 1, 2018: Palliative Medicine
https://www.readbyqxmd.com/read/29477452/incidence-management-and-implications-of-visceral-thrombosis-in-pancreatic-ductal-adenocarcinoma
#10
Angel Mier-Hicks, Michael Raj, Richard Kinh Do, Kenneth H Yu, Maeve A Lowery, Anna Varghese, Eileen M O'Reilly
BACKGROUND: Visceral or splanchnic thrombosis is defined as thrombi within the hepatoportal venous system, including portal (PV), mesenteric (MV), and splenic vein (SV), as well as thrombi in renal or gonadal veins. There are limited data to evaluate the prognostic significance, incidence, and clinical management of visceral thromboses in patients with pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: We conducted an analysis of 95 patients treated at Memorial Sloan Kettering Cancer Center with PDAC who had a visceral thrombosis...
January 31, 2018: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29470777/pleiotropic-effects-of-heparins-does-anticoagulant-treatment-increase-survival-in-cancer-patients
#11
REVIEW
I García-Escobar, C Beato-Zambrano, J Muñoz Langa, E Brozos Vázquez, B Obispo Portero, D Gutiérrez-Abad, A J Muñoz Martín
The association between venous thromboembolism (VTE) and cancer has been recognized for more than 100 years. Numerous studies have been performed to investigate strategies to decrease VTE incidence and to establish whether treating VTE impacts cancer progression and overall survival. Accordingly, it is important to understand the role of the hemostatic system in tumorigenesis and progression, as there is abundant evidence associating it with cell survival and proliferation, tumor angiogenesis, invasion, and dissemination, and metastasis formation...
February 22, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29460705/a-single-center-retrospective-cohort-study-comparing-low-molecular-weight-heparins-to-direct-oral-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer-a-real-world-experience
#12
Megan K Phelps, Tracy E Wiczer, H Paige Erdeljac, Kelsey R Van Deusen, Kyle Porter, Gary Philips, Tzu-Fei Wang
Introduction Low-molecular-weight heparins are the standard treatment for cancer-associated thrombosis. Recently, direct oral anticoagulants are a new option for thrombosis treatment; however, data supporting the use of direct oral anticoagulants for cancer-associated thrombosis are limited. Objectives The primary objective of this study was to determine the rate of recurrent cancer-associated thrombosis and major bleeding within 6 months of starting either low-molecular-weight heparin or direct oral anticoagulant for treatment of cancer-associated thrombosis...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29455568/effectiveness-and-safety-of-lmwh-treatment-in-patients-with-cancer-diagnosed-with-non-high-risk-venous-thromboembolism-turkish-observational-study-trebeca
#13
Ersin Ozaslan, Metin Ozkan, Irfan Cicin, Mustafa Benekli, Murat Kocer, Mukremin Uysal, Berna Oksuzoglu, Abdurrahman Isikdogan, Erdem Cubukcu, Emin T Elkiran, Faysal Dane, Mehmet Aliustaoglu, Alper Sevinc, Aziz Karaoglu, Arife Ulas, Gamze Gokoz-Dogu
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer who are at low risk of venous thromboembolism (VTE). Patients were treated by medical oncologists in Turkey at 15 sites, where they were enrolled and followed up for a period of 12 months. Due to the study design, there was no specific treatment protocol for LMWH. Primary end points were efficacy and the time to change in VTE status. Of the included 250 patients, 239 (95.6%), 176 (70.4%), 130 (52.0%), and 91 (36...
January 1, 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29417289/thromboprophylaxis-and-the-route-of-administration-of-chemotherapy-in-testicular-cancer-patients-in-german-speaking-countries
#14
Tim Nestler, Johannes Huber, Adrienne M Laury, Hendrik Isbarn, Axel Heidenreich, Hans U Schmelz, Christian G Ruf
PURPOSE: Due to the excellent cure rates for testicular cancer (TC), focus has shifted towards decreasing therapy-related morbidities. Thrombosis is a frequent complication of cisplatin chemotherapy. Furthermore, the optimal route of administration for chemotherapy is still under debate. The purpose of this study was to assess the patterns of care concerning dosing and duration of thromboprophylaxis currently utilized in TC patients in German-speaking countries as well as the route of chemotherapy administration...
February 7, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29409771/development-of-low-molecular-weight-heparin-based-nanoparticles-for-metastatic-breast-cancer-therapy
#15
Haifeng Sun, Dinglingge Cao, Hao Wu, Huan Liu, Xue Ke, Tianyuan Ci
Tumor metastasis is the primary obstacle in cancer treatment and is always the leading cause of human death. And heparin and its derivatives are potential anti-metastatic agents with good biocompatibility. In this work, low molecular weight heparin (LMWH) based LMWH-Cholesterol (LHC) conjugates were prepared for intravenous delivery of doxorubicin (DOX). The DOX/LHC nanoparticles (DOX/LHC NPs) exhibited a spherical shape with a mean diameter of 135.5 ± 2.2 nm and had a longer circulation time than that of DOX...
January 30, 2018: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29407633/the-lectin-pathway-and-coagulation-in-lung-cancer-patients-undergoing-lobectomy-a-randomised-controlled-trial
#16
Julie Brogaard Larsen, Anne Troldborg, Thomas Decker Christensen, Christine Lodberg Hvas, Steffen Thiel, Anne-Mette Hvas
BACKGROUND: Lectin pathway proteases activate coagulation and may theoretically play a role in the increased thrombosis risk in cancer, which is especially high during surgery. AIMS: To investigate lectin pathway proteins during lung cancer surgery, the influence of low molecular weight heparin (LMWH) on lectin pathway proteins, and correlations between lectin pathway proteins and coagulation. METHODS: Fifty lung cancer patients undergoing video-assisted thoracoscopic surgery lobectomy were randomised to LMWH, n = 26, or no anticoagulant (control), n = 24...
January 30, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29397103/caprini-risk-model-decreases-venous-thromboembolism-rates-in-thoracic-surgery-cancer-patients
#17
Helene M Sterbling, Amy K Rosen, Krista J Hachey, Niru S Vellanki, Philip D Hewes, Sowmya R Rao, Emma Pinjic, Hiran C Fernando, Virginia R Litle
BACKGROUND: Extended postoperative chemoprophylaxis is effective in reducing venous thromboembolism (VTE) among general surgical patients. We hypothesized that implementation of the Caprini risk assessment model (RAM) would reduce VTE rates among patients undergoing lung and esophageal cancer surgery. METHODS: The Caprini RAM, consisting of patient risk stratification and extended postoperative chemoprophylaxis with low molecular weight heparin, was implemented on the thoracic surgery service at Boston Medical Center in July 2014...
January 31, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29396864/effectiveness-and-safety-of-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer
#18
Michael Blake Streiff, Dejan Milentijevic, Keith McCrae, Daniel Yannicelli, Jonathan Fortier, Winnie W Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre, Jeff Schein, Alok A Khorana
Anticoagulation is used to treat venous thromboembolism (VTE) in cancer patients, but may be associated with an increased risk of bleeding. VTE recurrence and major bleeding were assessed in cancer patients treated for VTE with the most currently prescribed anticoagulants in clinical practice. Newly diagnosed cancer patients (first VTE 1/1/2013-05/31/2015) who initiated rivaroxaban, low-molecular-weight heparin (LMWH), or warfarin were identified from Humana claims data and observed until end of eligibility or end of data availability...
February 3, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29389673/low-molecular-weight-heparin-versus-rivaroxaban-in-the-treatment-of-venous-thromboembolism-in-gastrointestinal-malignancies
#19
Hannah K Choe, Maria T De Sancho, Sunnie S Kim, Tong Dai, Manish A Shah
: Due to their ease of use, the direct oral anticoagulants (DOACs) are an attractive treatment option for cancer-associated venous thromboembolism (VTE) and have been readily adopted by many clinicians. A recent published study comparing a DOAC (edoxaban) to the current standard-of-care low molecular weight heparin dalteparin for the treatment of cancer-associated thrombosis showed that edoxaban was noninferior to dalteparin for recurrent VTE, but the risk of major bleeding was higher. We present three patients with high-risk gastrointestinal malignancies complicated by cancer-associated VTE with progression of thrombosis while treated with the oral direct Xa inhibitor rivaroxaban...
March 2018: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/29384941/concomitant-coronary-and-pulmonary-embolism-associated-with-patent-foramen-ovale-a-case-report
#20
Zhongxiu Chen, Chen Li, Yajiao Li, Hong Tang, Li Rao, Mian Wang
RATIONALE: The differential diagnosis of acute chest pain is very important, and can sometimes be challenging. Related diseases share a number of risk factors, and occasionally, 1 condition causes another disease to develop. PATIENT CONCERNS: We described a 59-year-old man who presented to emergency department complaining of chest pain. DIAGNOSES: He was suffered acute myocardial infarction (MI) and pulmonary embolism (PE) simultaneously. INTERVENTIONS: Dual antiplatelet therapy, statin, and low molecular weight heparin were administrated during his stay...
December 2017: Medicine (Baltimore)
keyword
keyword
68448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"